IFN-β and multiple sclerosis: From etiology to therapy and back

Cytokine and Growth Factor Reviews

Volumn 26, Issue 2, 2015, Pages 221-228

  Annibali, V ^a   Mechelli, R ^a   Romano, S ^a   Buscarinu, M C ^a   Fornasiero, A ^a   Umeton, R ^a   Ricigliano, V A G ^a,b   Orzi, F ^a   Coccia, E M ^c   Salvetti, M ^a   Ristori, G ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Epstein Barr virus; Genome wide Association Studies; Human endogenous retroviruses; Interferon beta; Multiple sclerosis

Indexed keywords

ALPHA INTERFERON RECEPTOR; BETA INTERFERON; BETA1A INTERFERON; INTERFERON BETA SERINE; INTERFERON REGULATORY FACTOR 1; INTERFERON REGULATORY FACTOR 2; INTERFERON REGULATORY FACTOR 9; JANUS KINASE 1; JANUS KINASE 2; PEGINTERFERON BETA1A; PLACEBO; RALTEGRAVIR; RECOMBINANT BETA INTERFERON; STAT1 PROTEIN; STAT2 PROTEIN; IMMUNOLOGIC FACTOR; IMMUNOLOGICAL ADJUVANT; MACROGOL DERIVATIVE;

ANTIBODY TITER; ANTIVIRAL ACTIVITY; ARTICLE; COMPLEX FORMATION; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EPSTEIN BARR VIRUS; FLU LIKE SYNDROME; GENE EXPRESSION; GENETIC ASSOCIATION; HEPATITIS; HUMAN; HYPERTRANSAMINASEMIA; IMMUNOMODULATION; INJECTION SITE REACTION; INTRACELLULAR SIGNALING; LIVER FAILURE; LYMPHOCYTOPENIA; MOLECULAR PATHOLOGY; MULTIPLE SCLEROSIS; NEUROPATHOLOGY; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE NUCLEOTIDE POLYMORPHISM; VIRUS LOAD; VIRUS REPLICATION; HALF LIFE TIME; IMMUNOLOGY; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PATHOGENICITY; VIROLOGY;

HUMAN ENDOGENOUS RETROVIRUSES; HUMAN HERPESVIRUS 4;

ADJUVANTS, IMMUNOLOGIC; GENOME-WIDE ASSOCIATION STUDY; HALF-LIFE; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-BETA; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; POLYETHYLENE GLYCOLS;

EID: 84926470078     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2014.10.010     Document Type: Article

References (95)

1. Amato M.P., Ponziani G., Bartolozzi M.L., Siracusa G. A prospective study on the natural history of multiple sclerosis: clues to the conduct and interpretation of clinical trials. J Neurol Sci 1999, 168:96-106.
2. Scalfari A., Neuhaus A., Degenhardt A., Rice G.P., Muraro P.A., Daumer M., et al. The natural history of multiple sclerosis, a geographically based study: relapses and long-term disability. Brain 2010, 133:1914-1929.
3. Bordi I., Umeton R., Ricigliano V.A., Annibali V., Mechelli R., Ristori G., et al. A mechanistic, stochastic model helps understand multiple sclerosis course and pathogenesis. Int J Genomics 2013, 2013:910321.
4. Koch-Henriksen N. The Danish multiple sclerosis registry: a 50-year follow-up. Mult Scler 1999, 5:293-296.
5. International Multiple Sclerosis Genetics Consortium (IMSGC), Beecham A.H., Patsopoulos N.A., Xifara D.K., Davis M.F., Kemppinen A., et al. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet 2013, 45:1353-1360.
6. Ricigliano V.A., Umeton R., Germinario L., Alma E., Briani M., Di Segni N., et al. Contribution of genome-wide association studies to scientific research: a pragmatic approach to evaluate their impact. PLOS ONE 2013, 8:e71198.
7. Kakalacheva K., Lünemann J.D. Environmental triggers of multiple sclerosis. FEBS Lett 2011, 585:3724-3729.
8. Pender M.P. The essential role of Epstein-Barr virus in the pathogenesis of multiple sclerosis. Neuroscientist 2011, 17:351-367.
9. Almohmeed Y.H., Avenell A., Aucott L., Vickers M.A. Systematic review and meta-analysis of the sero-epidemiological association between Epstein Barr virus and multiple sclerosis. PLOS ONE 2013, 8:e61110.
10. Simon K.C., Munger K.L., Ascherio A. Vitamin D and multiple sclerosis: epidemiology, immunology, and genetics. Curr Opin Neurol 2012, 25:246-251.
11. Handel A.E., Williamson A.J., Disanto G., Dobson R., Giovannoni G., Ramagopalan S.V. Smoking and multiple sclerosis: an updated meta-analysis. PLoS ONE 2011, 6:e16149.
12. Sutkowski N., Conrad B., Thorley-Lawson D.A., Huber B.T. Epstein-Barr virus transactivates the human endogenous retrovirus HERV-K18 that encodes a superantigen. Immunity 2001, 15:579-589.
13. Antony J.M., Deslauriers A.M., Bhat R.K., Ellestad K.K., Power C. Human endogenous retroviruses and multiple sclerosis: innocent bystanders or disease determinants. Biochim Biophys Acta 2011, 1812:162-176.
14. Lünemann J.D. Epstein-Barr virus in multiple sclerosis: a continuing conundrum. Neurology 2012, 78:11-12.
15. Cohen J.I. Epstein-Barr virus infection. N Engl J Med 2000, 343:481-492.
16. Haahr S., Höllsberg P. Multiple sclerosis is linked to Epstein-Barr virus infection. Rev Med Virol 2006, 16:297-310.
17. Levin L.I., Munger K.L., Rubertone M.V., Peck C.A., Lennette E.T., Spiegelman D., et al. Temporal relationship between elevation of Epstein-Barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis. JAMA 2005, 293:2496-2500.
18. DeLorenze G.N., Munger K.L., Lennette E.T., Orentreich N., Vogelman J.H., Ascherio A. Epstein-Barr virus and multiple sclerosis: evidence of association from a prospective study with long-term follow-up. Arch Neurol 2006, 63:839-844.
19. Wagner H.J., Munger K.L., Ascherio A. Plasma viral load of Epstein-Barr virus and risk of multiple. Eur J Neurol 2004, 11:833-834.
20. Alotaibi S., Kennedy J., Tellier R., Stephens D., Banwell B. Epstein-Barr virus in pediatric multiple sclerosis. JAMA 2004, 291:1875-1879.
21. Banwell B., Krupp L., Kennedy J., Tellier R., Tenembaum S., Ness J., et al. Clinical features and viral serologies in children with multiple sclerosis: a multinational observational study. Lancet Neurol 2007, 6:773-781.
22. Handel A.E., Williamson A.J., Disanto G., Handunnetthi L., Giovannoni G., Ramagopalan S.V. An updated meta-analysis of risk of multiple sclerosis following infectious mononucleosis. PLoS ONE 2010, 5(9).
23. Cepok S., Zhou D., Srivastava R., Nessler S., Stei S., Büssow K., et al. Identification of Epstein-Barr virus proteins as putative targets of the immune response in multiple sclerosis. J Clin Invest 2005, 115:1352-1360.
24. Jilek S., Schluep M., Meylan P., Vingerhoets F., Guignard L., Monney A., et al. Strong EBV-specific CD8+ T-cell response in patients with early multiple sclerosis. Brain 2008, 131:1712-1721.
25. Jilek S., Schluep M., Harari A., Canales M., Lysandropoulos A., Zekeridou A., et al. HLAB7-restricted EBV specific CD8+ T cells are dysregulated in multiple sclerosis. J Immunol 2012, 188:4671-4680.
26. Angelini D.F., Serafini B., Piras E., Severa M., Coccia E.M., Rosicarelli B., et al. Increased CD8+ T cell response to Epstein-Barr virus lytic antigens in the active phase of multiple sclerosis. PLOS Pathog 2013, 9:e1003220.
27. Lünemann J.D., Edwards N., Muraro P.A., Hayashi S., Cohen J.I., Münz C., et al. Increased frequency and broadened specificity of latent EBV nuclear antigen-1-specific T cells in multiple sclerosis. Brain 2006, 129:1493-1506.
28. Ufret-Vincenty R.L., Quigley L., Tresser N., Pak S.H., Gado A., Hausmann S., et al. In vivo survival of viral antigen-specific T cells that induce experimental autoimmune encephalomyelitis. J Exp Med 1998, 188:1725-1738.
29. Lünemann J.D., Jelcić I., Roberts S., Lutterotti A., Tackenberg B., Martin R., et al. EBNA1-specific T cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN-gamma and IL-2. J Exp Med 2008, 205:1763-1773.
30. Lang H.L., Jacobsen H., Ikemizu S., Andersson C., Harlos K., Madsen L., et al. A functional and structural basis for TCR cross-reactivity in multiple sclerosis. Nat Immunol 2002, 3:940-943.
31. Serafini B., Rosicarelli B., Franciotta D., Magliozzi R., Reynolds R., Cinque P., et al. Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J Exp Med 2007, 204:2899-2912.
32. Serafini B., Severa M., Columba-Cabezas S., Rosicarelli B., Veroni C., Chiappetta G., et al. Epstein-Barr virus latent infection and BAFF expression in B cells in the multiple sclerosis brain: implications for viral persistence and intrathecal B-cell activation. J Neuropathol Exp Neurol 2010, 69:677-693.
33. Serafini B., Muzio L., Rosicarelli B., Aloisi F. Radioactive in situ hybridization for Epstein-Barr virus-encoded small RNA supports presence of Epstein-Barr virus in the multiple sclerosis brain. Brain 2013, 136:e233.
34. Mechelli R., Umeton R., Policano C., Annibali V., Coarelli G., Ricigliano V.A., et al. A candidate-interactome aggregate analysis of genome-wide association data in multiple sclerosis. PLOS ONE 2013, 8:e63300.
35. Aloisi F., Serafini B., Magliozzi R., Howell O.W., Reynolds R. Detection of Epstein-Barr virus and B-cell follicles in the multiple sclerosis brain: what you find depends on how and where you look. Brain 2010, 133:e157.
36. Lassmann H., Niedobitek G., Aloisi F., Middeldorp J.M., NeuroproMiSe EBV Working Group Epstein-Barr virus in the multiple sclerosis brain: a controversial issue-report on a focused workshop held in the Centre for Brain Research of the Medical University of Vienna, Austria. Brain 2011, 134:2772-2786.
37. Tzartos J.S., Khan G., Vossenkamper A., Cruz-Sadaba M., Lonardi S., Sefia E., et al. Association of innate immune activation with latent Epstein-Barr virus in active MS lesions. Neurology 2012, 78:15-23.
38. Jaquiéry E., Jilek S., Schluep M., Meylan P., Lysandropoulos A., Pantaleo G., et al. Intrathecal immune responses to EBV in early MS. Eur J Immunol 2010, 40:878-887. [Erratum in: Eur J Immunol 2011; 41:1501].
39. Lossius A., Johansen J.N., Vartdal F., Robins H., Jūrate˙ Šaltyte˙ B., Holmøy T., et al. High-throughput sequencing of TCR repertoires in multiple sclerosis reveals intrathecal enrichment of EBV-reactive CD8(+) T cells. Eur J Immunol 2014, August, [Epub ahead of print].
40. Power C. Retroviral diseases of the nervous system: pathogenic host response or viral gene-mediated neurovirulence?. Trends Neurosci 2001, 24:162-169.
41. Perron H., Garson J.A., Bedin F., Besème F.G., Paranhos-Baccala G., Komurian-Pradel F., et al. Molecular identification of a novel retrovirus repeatedly isolated from patients with multiple sclerosis. Proc Natl Acad Sci U S A 1997, 94:7583-7588.
42. Rieger F., Amouri R., Benjelloun N., Cifuentes-Diaz C., Dobransky T., Lyon-Caen O., et al. Gliotoxic factor and multiple sclerosis. C R Acad Sci 1996, 319:343-350.
43. Mameli G., Serra C., Astone V., Castellazzi M., Poddighe L., Fainardi E., et al. Inhibition of multiple-sclerosis-associated retrovirus as biomarker of interferon therapy. J Neurovirol 2008, 14:73-77.
44. Antony J.M., van Marle G., Opii W., Butterfield D.A., Mallet F., Yong V.W., et al. Human endogenous retrovirus glycoprotein-mediated induction of redox reactants causes oligodendrocyte death and demyelination. Nat Neurosci 2004, 7:1088-1095.
45. Perron H., Germi R., Bernard C., Garcia-Montojo M., Deluen C., Farinelli L., et al. Human endogenous retrovirus type W envelope expression in blood and brain cells provides new insights into multiple sclerosis disease. Mult Scler 2012, 18:1721-1736.
46. Isaacs A., Lindenmann J. Virus interference: I. The interferon. Proc R Soc Lond B: Biol Sci 1957, 147:258-267.
47. Pantich H.S., Hirsch R.L., Schindler J., Johnson K.P. Treatment of multiple sclerosis with gamma-interferons: exacerbations associated with activation on immune system. Neurology 1987, 37:1097-1102.
48. Pantich H.S., Hirsch R.L., Haley A.S., Johnson K.P. Exacerbations of multiple sclerosis in patients treated with gamma-interferon. Lancet 1987, 1:893-895.
49. Knobler R.L., Panitch H.S., Braheny S.L., Sipe J.C., Rice G.P., Huddlestone J.R., et al. Systemic alpha-interferontherapy of multiple sclerosis. Neurology 1984, 34:1273-1279.
50. Panitch H.S. Systemic alpha-interferon in multiple sclerosis. Long-term patient follow-up. Arch Neurol 1987, 44:61-63.
51. Camenga D.L., Johnson K.P., Alter M., Engelhardt C.D., Fishman P.S., Greenstein J.I., et al. Systemic recombinant alpha-2 interferon therapy in relapsing multiple sclerosis. Arch Neurol 1986, 43:1239-1246.
52. Durelli L., Bongioanni M.R., Cavallo R., Ferrero B., Ferri R., Ferrio M.F., et al. Chronic systemic high-dose recombinant interferon alfa-2a reduces exacerbation rate. MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing-remitting multiple sclerosis. Neurology 1994, 44(3 Pt 1):406-413.
53. Durelli L., Bongioanni M.R., Ferrero B., Ferri R., Imperiale D., Bradac G.B., et al. Interferon alpha-2a treatment of relapsing-remitting multiple sclerosis: disease activity resumes after stopping treatment. Neurology 1996, 47:123-129.
54. European Study Group on Interferon Beta-1b in Secondary Progressive MS Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive MS. Lancet 1998, 352:1491-1497.
55. The IFNB Multiple Sclerosis Study Group Interferon β-1b is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993, 43:655-661.
56. Paty D.W., Li D.K. Interferon beta lb is effective in relapsing-remitting multiple sclerosis: II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993, 43:662-667.
57. Rudick R.A., Goodkin D.E., Jacobs L.D., Cookfair D.L., Herndon R.M., Richert J.R., et al. Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology 1997, 49:358-363.
58. Simon J.H., Jacobs L.D., Campion M., Wende K., Simonian N., Cookfair D.L., et al. Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group. Ann Neurol 1998, 43:79-87.
59. PRISMS (Prevention of Relapses Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998, 352:1498-1504.
60. Panitch H., Miller A., Paty D., Weinshenker B. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology 2004, 63:1788-1795. North American Study Group on Interferon beta-1b in Secondary Progressive MS.
61. Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1a in MS (SPECTRIMS) Study Group Randomized controlled trial of interferon-beta-1a in secondary progressive MS: clinical results. Neurology 2001, 56:1496-1504.
62. Li D.K., Zhao G.J., Paty D.W. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results. Neurology 2001, 56:1505-1513. University of British Columbia MS/MRI Analysis Research Group The SPECTRIMS Study Group.
63. Cohen J.A., Cutter G.R., Fischer J.S., Goodman A.D., Heidenreich F.R., Kooijmans M.F., et al. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology 2002, 59:679-687.
64. Jacobs L.D., Beck R.W., Simon J.H., Kinkel R.P., Brownscheidle C.M., Murray T.J., et al. Intramuscular interferon-beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 2000, 343:898-904.
65. Comi G., Filippi M., Barkhof F., Durelli L., Edan G., Fernandez O., et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomized study. Lancet 2001, 357:1576-1582.
66. Kappos L., Polman C.H., Freedman M.S., Edan G., Hartung H.P., Miller D.H., et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006, 67:1242-1249.
67. Panitch H., Goodin D.S., Francis G., Chang P., Coyle P.K., O'Connor P., et al. Randomized, comparative study of interferon b-1a treatment regimens in MS. The EVIDENCE Trial. Neurology 2002, 59:1496-1506.
68. Durelli L., Verdun E., Barbero P., Bergui M., Versino E., Ghezzi A., et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomized multicentre study (INCOMIN). Lancet 2002, 359:1453-1460.
69. McGraw C.A., Lublin F.D. Interferon beta and glatiramer acetate therapy. Neurotherapeutics 2013, 10:2-18.
70. Rudick R.A., Lee J.C., Simon J., Ransohoff R.M., Fisher E. Defining interferon beta response status in multiple sclerosis patients. Ann Neurol 2004, 56:548-555.
71. Ross C., Clemmesen K., Svenson M., Sørensen P.S., Koch-Henriksen N., Skovgaard G.L., et al. Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Ann Neurol 2000, 48:706-712.
72. Calabresi P.A., Kieseier B.C., Arnold D.L., Balcer L.J., Boyko A., Pelletier J., et al. Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurol 2014, 13:657-665.
73. Kappos L., Clanet M., Sandberg-Wollheim M., Radue E.W., Hartung H.P., Hohlfeld R., et al. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study. Neurology 2005, 65:40-47.
74. Lycke J., Svennerholm B., Hjelmquisit E., Frisén L., Badr G., Andersson M., et al. Acyclovir treatment of relapsing-remitting multiple sclerosis a randomized, placebo-controlled, double-blind study. J Neurol 1996, 243:214-224.
75. Bech E., Lycke J., Gadeberg P., Hansen H.J., Malmeström C., Andersen O., et al. A randomized, double-blind, placebo-controlled MRI study of anti-herpes virus therapy in MS. Neurology 2002, 58:31-36.
76. Friedman J.E., Zabriskie J.B., Plank C., Ablashi D., Whitman J., Shahan B., et al. A randomized clinical trial of valacyclovir in multiple sclerosis. Mult Scler 2005, 11:286-295.
77. Lycke J., Andersen O., Svennerholm B., Appelgren L., Dahllof C. Acyclovir concentrations in serum and cerebrospinal fluid at steady state. J Antimicrob Chemother 1989, 24:947-954.
78. Ivashkiv L.B., Donlin L.T. Regulation of type I interferon responses. Nat Rev Immunol 2014, 14:36-49.
79. Killestein J., Polman C.H. Determinants of interferon β efficacy in patients with multiple sclerosis. Nat Rev Neurol 2011, 7(4):221-228.
80. Taniguchi T., Takaoka A. A weak signal for strong responses: interferon-alpha/beta revisited. Nat Rev Mol Cell Biol 2001, 2:378-386.
81. Li P., Wong J.J., Sum C., Sin W.X., Ng K.Q., Koh M.B., et al. IRF8 and IRF3 cooperatively regulate rapid interferon-β induction in human blood monocytes. Blood 2011, 117:2847-2854.
82. Bentz G.L., Liu R., Hahn A.M., Shackelford J., Pagano J.S. Epstein-Barr virus BRLF1 inhibits transcription of IRF3 and IRF7 and suppresses induction of interferon-beta. Virology 2010, 402:121-128.
83. Hahn A.M., Huye L.E., Ning S., Webster-Cyriaque J., Pagano J.S. Interferon regulatory factor 7 is negatively regulated by the Epstein-Barr virus immediate-early gene, BZLF-1. J Virol 2005, 79:10040-10052.
84. Valente R.M., Ehlers E., Xu D., Ahmad H., Steadman A., Blasnitz L., et al. Toll-like receptor 7 stimulates the expression of Epstein-Barr virus latent membrane protein 1. PLoS ONE 2012, 7:e43317.
85. Ning S., Hahn A.M., Huye L.E., Pagano J.S. Interferon regulatory factor 7 regulates expression of Epstein-Barr virus latent membrane protein 1: a regulatory circuit. J Virol 2003, 77:9359-9368.
86. Fathallah I., Parroche P., Gruffat H., Zannetti C., Johansson H., Yue J., et al. EBV latent membrane protein 1 is a negative regulator of TLR9. J Immunol 2010, 185:6439-6447.
87. Zhao B., Zou J., Wang H., Johannsen E., Peng C.W., Quackenbush J., et al. Epstein-Barr virus exploits intrinsic B-lymphocyte transcription programs to achieve immortal cell growth. Proc Natl Acad Sci U S A 2011, 108:14902-14907.
88. Mechelli R., Manzari C., Policano C., Annese A., Picardi E., Umeton R., et al. Epstein-Barr virus genetic variants associated with multiple sclerosis. Neurology 2014, Manuscript submitted.
89. Comabella M., Kakalacheva K., Río J., Münz C., Montalban X., Lünemann J.D. EBV-specific immune responses in patients with multiple sclerosis responding to IFNβ therapy. Mult Scler 2012, 18:605-609.
90. Balashov K.E., Aung L.L., Vaknin-Dembinsky A., Dhib-Jalbut S., Weiner H.L. Interferon-β inhibits toll-like receptor 9 processing in multiple sclerosis. Ann Neurol 2010, 68:899-906.
91. Giacomini E., Severa M., Rizzo F., Mechelli R., Annibali V., Ristori G., et al. IFN-β therapy modulates B-cell and monocyte crosstalk via TLR7 in multiple sclerosis patients. Eur J Immunol 2013, 43:1963-1972.
92. Serra C., Mameli G., Arru G., Sotgiu S., Rosati G., Dolei A. In vitro modulation of the multiple sclerosis (MS)-associated retrovirus by cytokines: implications for MS pathogenesis. J Neurovirol 2003, 9:637-643.
93. Curtin F., Lang A.B., Perron H., Laumonier M., Vidal V., Porchet H.C., et al. GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus: a first-in-humans randomized clinical study. Clin Ther 2012, 34:2268-2278.
94. Dreyfus D.H. Autoimmune disease: a role for new anti-viral therapies. Autoimmun Rev 2011, 11:88-97.
95. Sorensen P.S., Ross C., Clemmesen K.M., Bendtzen K., Frederiksen J.L., et al. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 2003, 362:1184-1191.